

# Non-Hodgkin Lymphoma

**Protocol applies to non-Hodgkin lymphoma involving any organ system except the gastrointestinal tract.**

---

*Protocol revision date: January 2005  
No AJCC/UICC staging system*

## **Procedures**

- **Cytology** (No Accompanying Checklist)
- **Biopsy**
- **Resection of Lymph Node or Other Organ**

## **Authors**

Carolyn Compton, MD, PhD

Department of Pathology, McGill University, Montreal, Quebec, Canada

Jonathan Said, MD

Department of Pathology, UCLA School of Medicine, Los Angeles, California

For the Members of the Cancer Committee, College of American Pathologists

**Previous contributors:** Nancy L. Harris, MD; Dennis W. Ross, MD, PhD; Annik van den Abbeele, MD; Judith Ferry, MD; Claire Fung, MD; Irene Kuter, MD; Peter Mauch, MD

© 2005. College of American Pathologists. All rights reserved.

The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College.

The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the “Surgical Pathology Cancer Case Summary (Checklist)” portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice.

The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document.

**Summary of Changes to Checklist(s)**

*Protocol revision date: January 2005*

No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision.

**Surgical Pathology Cancer Case Summary (Checklist)**

*Protocol revision date: January 2005  
 Applies to non-gastrointestinal, non-Hodgkin lymphoma only  
 No AJCC/UICC staging system*

**NON-HODGKIN LYMPHOMA: Biopsy, Resection**

Patient name:  
 Surgical pathology number:

**Note: Check 1 response unless otherwise indicated.**

**MACROSCOPIC**

**Specimen Type**

- Lymphadenectomy
- Other (specify): \_\_\_\_\_
- Not specified

**Tumor Site (check all that apply)**

- Lymph node(s), site not specified
- Lymph node(s)  
 Specify site(s): \_\_\_\_\_
- Other tissue(s) or organ(s)  
 Specify site(s): \_\_\_\_\_
- Not specified

**MICROSCOPIC**

**Histologic Type (WHO Classification)**

- Histologic type cannot be assessed

**B-cell Lymphoma**

- B-cell lymphoma, subtype cannot be determined
- Precursor B-lymphoblastic leukemia/lymphoma
- Chronic lymphocytic leukemia/small lymphocytic lymphoma
- B-cell prolymphocytic leukemia
- Lymphoplasmacytic lymphoma
- Splenic marginal zone lymphoma
- Hairy cell leukemia
- Plasma cell myeloma/ Plasmacytoma
- Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)
- Nodal marginal zone B-cell lymphoma

4                    \* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

- Follicular lymphoma, grade 1 (0-5 centroblasts per HPF)
- Follicular lymphoma, grade 2 (6-15 centroblasts per HPF)
- Follicular lymphoma, grade 3 (greater than 15 centroblasts per HPF)
- Follicular lymphoma, cutaneous follicle center sub-type
- Follicular lymphoma, diffuse follicle center sub-type, grade 1 (0-5 centroblasts per HPF)
- Follicular lymphoma, diffuse follicle center cell sub-type, grade 2 (6-15 centroblasts per HPF)
- Mantle cell lymphoma
- Diffuse large B-cell lymphoma
- Mediastinal (thymic) large B-cell lymphoma
- Intravascular large B-cell lymphoma
- Primary effusion lymphoma
- Burkitt lymphoma/leukemia
- Lymphomatoid granulomatosis
- Other (specify): \_\_\_\_\_

T-cell Lymphoma

- T-cell lymphoma, subtype cannot be determined
- Precursor T-lymphoblastic leukemia/lymphoma
- T-cell prolymphocytic leukemia
- T-cell large granular lymphocytic leukemia
- Aggressive NK-cell leukemia
- Adult T-cell leukemia/lymphoma
- Extranodal NK/T-cell lymphoma, nasal type
- Enteropathy-type T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Subcutaneous panniculitis-like T-cell lymphoma
- Mycosis fungoides / Sézary syndrome
- Primary cutaneous anaplastic large cell lymphoma
- Peripheral T-cell lymphoma, unspecified
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large cell lymphoma
- Lymphomatoid papulosis
- Other (specify): \_\_\_\_\_

**Extent of Pathologically Examined Tumor (check all that apply)**

- Involvement of a single lymph node region  
Specify site: \_\_\_\_\_
- Involvement of multiple lymph node regions  
Specify: \_\_\_\_\_
- Splenic involvement
- Liver involvement
- Bone marrow involvement
- Other organ involvement  
Specify: \_\_\_\_\_
- Not specified

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.

**Phenotyping**

Performed, see separate report

Performed

Specify method and results: \_\_\_\_\_

Not performed

**\*Additional Pathologic Findings**

\*Specify: \_\_\_\_\_

**\*Comment(s)**

\* Data elements **with asterisks** are **not required** for accreditation purposes for the Commission on Cancer. These elements may be clinically important, but are not yet validated or regularly used in patient management. Alternatively, the necessary data may not be available to the pathologist at the time of pathologic assessment of this specimen.